human
metapneumoviru
paramyxoviru
discov
major
caus
lower
respiratori
infect
adult
children
worldwid
licens
vaccin
drug
human
metapneumoviru
develop
fluoresc
cellbas
mediumthroughput
screen
assay
human
metapneumoviru
captur
inhibitor
stage
viral
lifecycl
except
bud
progeni
viru
particl
cell
membran
optim
valid
assay
perform
success
mediumthroughput
screen
number
hit
identifi
sever
confirm
inhibit
viral
replic
secondari
assay
assay
offer
potenti
discov
new
antivir
human
metapneumoviru
relat
respiratori
virus
compound
discov
use
mediumthroughput
screen
may
also
provid
use
probe
viral
biolog
human
metapneumoviru
hmpv
paramyxoviru
discov
major
caus
lower
respiratori
infect
adult
children
worldwid
hmpv
close
relat
respiratori
syncyti
viru
lead
caus
bronchiol
pneumonia
young
children
hmpv
caus
hospit
previous
healthi
infant
highrisk
group
rate
compar
parainfluenza
virus
influenza
viru
children
becom
infect
age
five
hmpv
seropreval
adult
nearli
licens
vaccin
drug
hmpv
thu
unmet
need
antivir
sought
develop
mediumthroughput
screen
mt
inhibitor
hmpv
human
bronchial
epitheli
cell
atcc
cultur
optimem
life
technolog
medium
contain
fetal
bovin
serum
supplement
amphotericin
gentamicin
lglutamin
incub
c
co
hmpv
isol
subgroup
use
experi
viru
propag
titrat
use
cell
describ
previous
virusinfect
cell
posit
signal
detect
immunofluoresc
stain
human
monoclon
antibodi
mab
hmpv
fusion
f
protein
goat
antihuman
ig
irdy
cw
licor
bioscienc
potent
hmpvneutral
human
mab
specif
hmpv
f
protein
use
inhibit
control
mab
titrat
screen
exhibit
inhibit
viru
signal
serv
mean
mt
perform
duplic
three
compound
librari
spectrum
collect
microsourc
discoveri
system
compris
compound
wide
rang
biolog
activ
structur
divers
nih
clinic
collect
contain
total
compound
previous
use
human
clinic
trial
http
wwwnihclinicalcollect
com
final
bioactiv
lipid
screen
librari
cayman
chemic
contain
bioactiv
lipid
individu
compound
secondari
confirm
hit
purchas
sigma
dissolv
dmso
dilut
optimem
vitro
test
cell
dispens
black
clearbottom
plate
bd
falcon
densiti
cellswel
optimem
medium
use
multidrop
combi
thermo
scientif
incub
h
ten
microlit
compound
ad
use
bravo
liquid
handler
agil
result
final
drug
concentr
mm
dmso
four
hour
compound
addit
cell
infect
hmpv
use
multidrop
combi
multipl
infect
moi
pfucel
incub
h
posit
neg
control
includ
plate
incub
buffer
formalin
ad
use
multidrop
combi
fix
room
temperatur
min
wash
tween
pbst
plate
block
nonfat
dri
milk
pbst
min
stain
primari
mab
min
wash
pbst
stain
secondari
antihuman
igg
min
wash
pbst
stain
plasma
membran
cell
dye
life
technolog
min
wash
pbst
plate
read
odyssey
infrar
imag
licor
use
automat
mode
dynam
rang
bit
viru
signal
read
nm
channel
cell
signal
nm
channel
raw
fluoresc
data
analyz
use
algorithm
adjust
variabl
across
control
plate
compens
degre
cell
toxic
relat
degre
viral
suppress
well
categor
potenti
hit
exhibit
statist
signific
reduct
viru
signal
standard
deviat
sd
mean
inhibit
viru
signal
mab
entir
screen
perform
twice
separ
run
one
week
apart
cell
monolay
treat
compound
inocul
hmpv
moi
pfucel
cell
incub
h
hmpv
serumfre
growth
medium
consist
optimem
mgml
trypsin
life
technolog
cell
viabil
secondari
assay
perform
use
celltiterglo
assay
promega
mevastatin
simvastatin
stain
primari
mt
compound
monolay
fix
viral
infect
read
stain
mab
fluoresc
secondari
ab
transcript
translat
hmpv
protein
occur
within
h
follow
viru
entri
surfac
viral
protein
express
within
h
infecti
progeni
virion
produc
h
therefor
design
assay
infect
cell
monolay
hmpv
perform
readout
infect
immunostain
viral
protein
express
cell
surfac
h
thu
assay
captur
step
viru
lifecycl
except
bud
progeni
virion
includ
cell
viabil
dye
normal
signal
cell
number
discrimin
specif
antivir
effect
cell
toxic
test
multipl
antibodi
cell
dye
concentr
condit
optim
data
shown
layout
assay
plate
shown
figur
sensit
dynam
rang
determin
use
serial
dilut
neutral
mab
hmpv
posit
control
inhibit
exhibit
micromolar
activ
neutral
mgml
complet
inhibit
hmpv
mgml
previous
shown
establish
reproduc
assay
measur
fluoresc
cell
infect
hmpv
treat
without
neutral
mab
perform
triplic
differ
day
allow
us
determin
welltowel
platetopl
daytoday
variat
use
data
measur
mean
fluoresc
mabtreat
untreat
sampl
determin
coeffici
variat
neg
signal
cell
alon
well
posit
signal
cell
viru
well
key
measur
suitabl
screen
assay
z
defin
formula
z
standard
deviat
posit
standard
deviat
neg
mean
positivemean
neg
z
assay
within
desir
rang
figur
determin
reduc
signal
due
cell
toxic
key
aspect
assay
compound
toxic
reduc
viru
signal
nonspecif
consequ
reduc
cell
signal
figur
howev
compound
exhibit
clear
virusspecif
effect
reduct
viru
signal
retain
cell
signal
figur
fiftyon
compound
identifi
statist
reduc
viru
signal
sd
mean
supplement
tabl
candid
hit
fell
three
main
categori
hmgcoa
reductas
inhibitor
statin
b
dna
topoisomeras
inhibitor
c
host
factor
inhibitor
sever
compound
identifi
report
exhibit
vitro
activ
rna
virus
tabl
hit
biolog
replic
screen
confirm
whether
candid
exhibit
specif
activ
hmpv
test
serial
dilut
select
compound
tabl
singlecycl
viral
growth
assay
measur
viru
signal
cell
viabil
signal
compound
chosen
test
secondari
assay
base
biolog
plausibl
hmgcoa
reductas
inhibitor
frequenc
hit
compound
class
topoisomeras
inhibitor
prior
report
antivir
activ
mevastatin
simvastatin
exhibit
modest
dosedepend
antivir
effect
hmpv
cellular
toxic
dose
rang
luminesc
cell
viabil
assay
figur
acacetin
isoproterenol
exhibit
signific
antivir
cytotox
effect
secondari
assay
figur
howev
irinotecan
etoposid
ciclopirox
exhibit
dosedepend
cytotox
modest
inhibit
hmpv
addit
cytotox
figur
design
perform
mt
inhibitor
hmpv
import
human
pathogen
assay
exhibit
accept
z
score
amen
autom
show
feasibl
screen
much
larger
compound
librari
discov
number
compound
antivir
activ
sever
demonstr
dosedepend
inhibit
hmpv
independ
cellular
toxic
particularli
intrigu
multipl
statin
identifi
screen
hmgcoa
reductas
inhibitor
statin
associ
milder
diseas
improv
outcom
influenza
infect
human
although
mechan
unknown
clinic
trial
offer
conflict
result
statin
shown
inhibit
endocytosi
influenza
viru
hmpv
enter
cell
endocytosi
make
identif
statin
endocytosi
inhibitor
chlorprothixen
interest
inde
statin
inhibit
hmpv
infect
howev
hmpv
capabl
enter
cell
plasma
membran
via
endocytosi
thu
partial
inhibit
hmpv
statin
figur
may
due
preserv
viral
entri
cell
surfac
inhibit
endocytosi
inhibitor
statin
competit
inhibitor
hmgcoa
reductas
ratelimit
step
mevalon
pathway
addit
role
inhibit
cholesterol
biosynthesi
statin
also
impact
cellular
process
statin
inhibit
prenyl
protein
well
inhibit
cholesterol
biosynthesi
data
prenyl
hmpv
protein
prenyl
viral
protein
proven
import
hepat
viru
thought
import
hiv
hsv
futur
studi
may
elucid
mechan
hmpv
inhibit
statin
aurintricarboxyl
acid
topoisomeras
inhibitor
vitro
antivir
activ
number
rna
virus
mediat
inhibit
viral
rna
polymeras
interestingli
assay
number
hit
topoisomeras
inhibitor
class
exhibit
antivir
effect
also
substanti
cytotox
suggest
antivir
effect
occur
antiprolif
mechan
howev
topoisomeras
inhibitor
camptothecin
exhibit
antivir
activ
positivesens
rna
viru
enteroviru
mediat
topoisomeras
reloc
cytoplasm
interact
viral
protein
studi
need
explor
biolog
relev
topoisomeras
inhibitor
effect
hmpv
result
show
mt
capabl
identifi
lead
compound
vitro
activ
mev
sim
test
cytotox
use
celltiterglo
assay
promega
result
plot
right
axi
dot
mean
ae
sd
hmpv
human
metapneumoviru
hmpv
method
provid
proof
concept
capac
screen
much
larger
librari
experi
need
explor
modif
drug
use
medicin
chemistri
enhanc
antivir
potenc
identifi
mechan
action
studi
offer
promis
develop
new
antivir
hmpv
